Carbapenem-resistant Enterobacterales acquisition following piperacillin-tazobactam versus carbapenem treatment: a propensity-matched cohort study
Clinical Microbiology and Infection · 2025
DOI: 10.1016/j.cmi.2025.04.006 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Microbiology and Infection, 2025. Verfasst von Hagar Dallasheh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medicine B and H, Rambam Health Care Campus, Haifa, Israel. Electronic address: hajar.dallashi@gmail.com. Hauptthemen laut MEDLINE: Piperacillin, Tazobactam Drug Combination, Carbapenems, Anti-Bacterial Agents, Enterobacteriaceae Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: We aimed to quantify the ecological consequences of carbapenems versus piperacillin-tazobactam treatment on the risk of carbapenem-resistant Enterobacterales (CRE) acquisition. METHODS: We conducted a retrospective cohort study with propensity-score matching. The study was conducted in a single large hospital in Israel from 2014 to 2023. We included all adult patients treated with piperacillin-tazobactam (PTZ) or a carbapenem for at least 5 days. We excluded patients with known carriage of CRE at treatment initiation and patients in the PTZ group who received a carbapenem within 30 days before or 90 days after the start of PTZ. The outcome assessed was CRE acquisition through surveillance or clinical samples from day 5 to day 90 after treatment initiation. The propensity score for treatment selection was derived to match patients in the treatment groups using 1:1 nearest-neighbour matching with a calliper of 0.01. A sensitivity analysis of the full cohort was performed through a regression model of CRE acquisition, adjusting the analysis using inverse probability of treatment weighting. RESULTS: We included 7731 patients, of whom 6.2% (483/7731) acquired CRE: 4.5% (219/4887) of patients treated with PTZ versus 9.3% (264/2844) of patients treated with a carbapenem (unadjusted odds ratio [OR] 0.46, 95% CI, 0.38-0.55). In the matched cohort, CRE acquisition occurred in 6.4% (130/2018) of patients treated with PTZ versus 8.7% (175/2018) of patients treated with carbapenems (propensity score-matched OR 0.72.95% CI, 0.57-0.92). Independent risk factors for CRE acquisition included hospitalization in the haemao-oncology or neurosurgical wards, longer antibiotic exposure and hospitalization, bloodstream infections, low albumin and higher glucose levels. Adjusted to these and weighted by the inverse probability of treatment, PTZ was associated with CRE acquisition with an OR of 0.81, 95% CI, (0.66-0.98). DISCUSSION: Carbapenem were significantly associated with CRE acquisition compared with PTZ in a CRE endemic settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicine B and H, Rambam Health Care Campus, Haifa, Israel. Electronic address: hajar.dallashi@gmail.com.
- Infectious Diseases Division, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Zitieren
APA
Dallasheh, H., & Paul, M. (2025). Carbapenem-resistant Enterobacterales acquisition following piperacillin-tazobactam versus carbapenem treatment: a propensity-matched cohort study. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2025.04.006
Vancouver
Dallasheh H, Paul M. Carbapenem-resistant Enterobacterales acquisition following piperacillin-tazobactam versus carbapenem treatment: a propensity-matched cohort study. Clinical Microbiology and Infection. 2025. doi:10.1016/j.cmi.2025.04.006
BibTeX
@article{Dallasheh2025,
author = {Dallasheh, Hagar and Paul, Mical},
title = {Carbapenem-resistant Enterobacterales acquisition following piperacillin-tazobactam versus carbapenem treatment: a propensity-matched cohort study},
journal = {Clinical Microbiology and Infection},
year = {2025},
doi = {10.1016/j.cmi.2025.04.006}
}
EUVIMED